COVID-19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group

Basit Öğe Kaydı
dc.contributor.authorBozkurt, Ceyhun
dc.contributor.authorHazar, Volkan
dc.contributor.authorMalbora, Baris
dc.contributor.authorKupesiz, Alphan
dc.contributor.authorAygunes, Utku
dc.contributor.authorFisgin, Tunc
dc.contributor.authorKarakukcu, Musa
dc.date.accessioned2024-05-19T14:38:52Z
dc.date.available2024-05-19T14:38:52Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackgroundData on the risk factors and outcomes for pediatric patients with SARS-CoV-2 infection (COVID-19) following hematopoietic stem cell transplantation (HSCT) are limited.ObjectivesThe study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID-19 infection.MethodIn this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID-19 between March 2020 and August 2022.ResultsThe median time from HSCT to COVID-19 infection was 209.0 days (IQR, 111.7-340.8; range, 0-3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID-19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS-C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID-19-related mortality.ConclusionWhile COVID-19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS-C or LRTD. COVID-19 in children following HSCT is frequently asymptomatic/mild. Nonetheless, 12% of patients have such severe disease that they need intensive care. Adverse outcomes are expected in mismatched HSCT, lymphopenia, LRTD, and MIS-C.imageen_US
dc.description.sponsorshipAmerican Journal Expertsen_US
dc.description.sponsorshipWe acknowledge the support of American Journal Experts for native editing.en_US
dc.identifier.doi10.1111/petr.14758
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85191193300en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.1111/petr.14758
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4636
dc.identifier.volume28en_US
dc.identifier.wosWOS:001207499700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAdolescentsen_US
dc.subjectChildrenen_US
dc.subjectCovid-19en_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.titleCOVID-19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu